Director of Immuno-Oncology Research

POSITION SUMMARY:

Pulse Biosciences, Inc. is an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) platform. Preclinical studies using NPS on solid tumors in murine models has demonstrated that NPS enables effective local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic cell death. We are expanding our preclinical immuno-oncology program and adding a new role, Director of Immuno-Oncology Research.

The successful candidate will be responsible for leading a cancer biology team focused on preclinical proof of concept, optimization and preclinical development for advancing NPS applications in solid tumors into the clinic.  Emphasis will be the delineation and articulation of NPS therapy’s impact on the immune response, tumor biology, tissue and tumor microenvironment in translatable preclinical studies. The Director, Immuno-Oncology Research will work closely with our Chief Scientific Officer and will partner with the leadership team to help translate the corporate IO strategy into a research plan with near- and long-term goals.

The candidate will have in-depth knowledge of the fundamentals of cancer immunotherapy including immunology, tumor biology, cell death mechanisms and the tumor microenvironments in solid malignancies. The ideal candidate will have significant experience leading projects in a collaborative manner preferentially in an industry setting.

ESSENTIAL DUTIES AND RESPONSIBILITIES:

QUALIFICATIONS:

To perform this job successfully, an individual must be able to perform each essential duty satisfactorily.  The requirements listed below are representative of the knowledge, skill, and/or ability required. 

EDUCATION and/or EXPERIENCE:

COMPANY OVERVIEW:

Pulse Biosciences, Inc. is an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) platform. Preclinical studies using NPS on solid tumors in murine models has demonstrated that NPS enables effective local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic cell death.

Pulse Biosciences, Inc. (PLSE, Nasdaq) corporate headquarters is located in Hayward, CA.

CONTACT: